EUVIMEDEUVIMED entdecken
Crossref

Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample

Wanfang Zhang iD, Vinay Bhandaru, Nicholas E Johnson iD, Amy Moore, Abigail Lyons, Reba Berry, Christina Westfield, Daria McMahon iD, Aida Soim, Bo Cai, Suzanne McDermott, MD STARnet

Muscle & Nerve · 2025-10 · 72 (4) · 570-579

DOI: 10.1002/mus.28464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 30.06.2025. Verfasst von Wanfang Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CDC HHS, NINDS NIH HHS, NCBDD CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aim To optimize patient care and cancer screening in myotonic dystrophy (DM), it is crucial to clarify cancer risks by DM type to guide targeted screening and prevention efforts. This study describes the prevalence of cancer among individuals diagnosed with DM from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), and compares it to cancer prevalence in the US Surveillance, Epidemiology, and End Result (SEER) data.

Methods

This retrospective cohort study used 2008–2019 medical records data on 1229 individuals diagnosed with DM (DM1: 81.4%, DM2: 9.4%, DM‐not otherwise specified [NOS]: 9.2%) from MD STARnet. Age‐ and sex‐specific cancer prevalence rates from SEER were applied to the MD STARnet data to calculate 12‐year limited duration (LD) and complete standardized prevalence ratios (SPR) for total cancer and by primary cancer site.

Results

Over a 12‐year span, individuals with DM1 had a 4.01‐fold higher LD prevalence of thyroid cancer and a 17.97‐fold higher LD prevalence of nonmelanoma skin cancer compared to the SEER prevalence, respectively. Complete prevalence assessments identified that individuals with DM1 had a 4.18‐fold higher prevalence of thyroid cancer, a 2.36‐fold higher prevalence of melanoma, and a 4.68‐fold higher prevalence of ovarian cancer. For DM2, the study observed a 34.02‐fold higher LD prevalence for nonmelanoma skin cancer. Additionally, a significantly elevated complete prevalence of breast cancer (2.65‐fold) was noted for DM2 compared to SEER data.

Discussion

Future research with larger cohorts is needed to define cancer risks by DM subtype and investigate underlying biological mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyNeoplasmsHumansFemaleMalePrevalenceMiddle AgedRetrospective StudiesAdultAgedUnited StatesSEER ProgramYoung AdultCohort StudiesAdolescentThyroid NeoplasmsSkin Neoplasms

Stichwörter der Autor:innen

MD STARnetSEERcancermyotonic dystrophyprevalencestandardized prevalence rate

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA.
  • Biostatistics Center, George Washington University, Washington, DC, USA.
  • Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.
  • RTI International, Research Triangle Park, North Carolina, USA.
  • Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health & Health Policy, City University of New York, New York, New York, USA.
  • Division of Population Health Surveillance, Department of Health, Bureau of Maternal and Child Health, Columbia, South Carolina, USA.

ORCID-Profile: Wanfang Zhang, Nicholas E Johnson, Daria McMahon

Förderung

  • CDC HHS
  • NINDS NIH HHS
  • NCBDD CDC HHS
  • Centers for Disease Control and Prevention
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Zhang, W., Bhandaru, V., Johnson, N. E., Moore, A., Lyons, A., Berry, R., Westfield, C., McMahon, D., Soim, A., Cai, B., McDermott, S., & MD STARnet (2025). Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample. Muscle & Nerve, 72(4), 570-579. https://doi.org/10.1002/mus.28464

Vancouver

Zhang W, Bhandaru V, Johnson NE, Moore A, Lyons A, Berry R, et al. Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample. Muscle & Nerve. 2025;72(4):570-579. doi:10.1002/mus.28464

BibTeX
@article{Zhang2025,
  author = {Zhang, Wanfang and Bhandaru, Vinay and Johnson, Nicholas E and Moore, Amy and Lyons, Abigail and Berry, Reba and Westfield, Christina and McMahon, Daria and Soim, Aida and Cai, Bo and McDermott, Suzanne and MD STARnet, MD STARnet},
  title = {Elevated Cancer Prevalence Identified at Specific Anatomical Sites Among People With Myotonic Dystrophy Using a Population‐Based Sample},
  journal = {Muscle & Nerve},
  year = {2025},
  volume = {72},
  number = {4},
  pages = {570--579},
  doi = {10.1002/mus.28464}
}
Kostenlos starten →